Artivion, Inc. (NYSE:AORT) Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC reduced its position in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 3.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,074,603 shares of the company's stock after selling 37,057 shares during the period. GW&K Investment Management LLC owned about 2.52% of Artivion worth $26,414,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. New York State Common Retirement Fund boosted its stake in Artivion by 104.2% in the first quarter. New York State Common Retirement Fund now owns 83,754 shares of the company's stock valued at $2,059,000 after acquiring an additional 42,737 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Artivion by 2.4% in the first quarter. Principal Financial Group Inc. now owns 206,777 shares of the company's stock valued at $5,083,000 after acquiring an additional 4,749 shares in the last quarter. Peregrine Capital Management LLC acquired a new position in Artivion in the first quarter valued at $7,650,000. Illinois Municipal Retirement Fund boosted its stake in Artivion by 3.1% in the first quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock valued at $504,000 after acquiring an additional 611 shares in the last quarter. Finally, Legacy Advisors LLC acquired a new position in Artivion in the first quarter valued at $28,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Canaccord Genuity Group assumed coverage on shares of Artivion in a report on Tuesday, June 17th. They issued a "buy" rating and a $35.00 target price for the company. JMP Securities reaffirmed a "market outperform" rating and issued a $33.00 target price on shares of Artivion in a report on Tuesday, May 6th. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 target price on shares of Artivion in a report on Tuesday, May 6th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Artivion has an average rating of "Buy" and a consensus price target of $32.40.

Insiders Place Their Bets

In other Artivion news, SVP Jean F. Holloway sold 9,926 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.00, for a total transaction of $287,854.00. Following the transaction, the senior vice president directly owned 187,258 shares in the company, valued at approximately $5,430,482. This represents a 5.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Anthony B. Semedo sold 2,600 shares of the company's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $28.47, for a total transaction of $74,022.00. Following the transaction, the director owned 33,059 shares in the company, valued at $941,189.73. The trade was a 7.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,954 shares of company stock worth $2,108,525. 7.60% of the stock is owned by company insiders.

Artivion Stock Performance

NYSE AORT traded down $0.06 during trading hours on Thursday, hitting $31.18. 117,324 shares of the stock were exchanged, compared to its average volume of 423,148. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -62.32 and a beta of 1.62. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $32.94. The stock has a 50-day moving average of $29.99 and a 200 day moving average of $27.83. The company has a quick ratio of 3.95, a current ratio of 5.53 and a debt-to-equity ratio of 1.08.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. The firm had revenue of $98.98 million for the quarter, compared to analysts' expectations of $94.81 million. As a group, equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.